Fifty-two weeks of Tezepelumab significantly reduces nasal polyp severity and the need for surgery in adults with chronic rhinosinusitis according to new research presented at the 2025 AAAAI / WAO Joint Congress. #AAAAI25 #rhinosinusitis #NasalPolyp
www.aaaai.org/about/news/n...